Coherus Oncology, Inc.
Every calculator, already run for CHRS
Open the full toolkit →You have the numbers on CHRS. Get the argument.
A written report on which of these readings actually decide the outcome for Coherus Oncology, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
6 analysts covering CHRSAnalyst Price Target Disagreement for Coherus Oncology, Inc.
Wall Street's bull case implies +762% from the current price; the bear case implies +245%. A 517% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for CHRS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Coherus Oncology, Inc.
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It ha…
CHRS — frequently asked
Is CHRS a buy right now?
Wall Street's consensus rating on Coherus Oncology, Inc. is none across 6 analysts, with a mean price target of $7.75 (+568% vs. the current $1.16). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is CHRS's next earnings date?
Coherus Oncology, Inc. is next scheduled to report earnings around Nov 5, 2026. A full CHRS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Coherus Oncology, Inc.?
Analysts covering Coherus Oncology, Inc. (CHRS) range from a bear-case target of $4.00 to a bull-case high of $10.00, with a mean consensus target of $7.75 across 4 analysts. The spread of $6.00 (517% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Coherus Oncology, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Coherus Oncology, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CHRS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Coherus Oncology, Inc., in minutes. 3 free reports included with every account — no credit card required.